Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
Status:
Not yet recruiting
Trial end date:
2024-06-15
Target enrollment:
Participant gender:
Summary
This study will be a randomized, double-blind, placebo-controlled clinical trial comparing
the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients (KTR) with
pre-existing type. diabetes (T2D) or post-transplant diabetes mellitus (PTDM). The primary
outcome of the trial is to determine if dapagliflozin is superior to placebo in reduction of
blood pressure in KTR.